Post-Remission Therapy in Acute Myeloblastic Leukemia a randomized trial comparing early consolidation plus maintenance versus maintenance therapy alone

Authors

  • J. Maldonado Pethema Spanish Cooperative Group for Hematological Malignancies Treatment, Spanish Society of Hematology, Spain
  • S. Gardella Pethema Spanish Cooperative Group for Hematological Malignancies Treatment, Spanish Society of Hematology, Spain
  • J. M. Rodriguez Fernandez Pethema Spanish Cooperative Group for Hematological Malignancies Treatment, Spanish Society of Hematology, Spain
  • R. Parody Pethema Spanish Cooperative Group for Hematological Malignancies Treatment, Spanish Society of Hematology, Spain
  • J. Muncunill Pethema Spanish Cooperative Group for Hematological Malignancies Treatment, Spanish Society of Hematology, Spain
  • P. Vivancos Pethema Spanish Cooperative Group for Hematological Malignancies Treatment, Spanish Society of Hematology, Spain
  • C. Alonso Pethema Spanish Cooperative Group for Hematological Malignancies Treatment, Spanish Society of Hematology, Spain
  • L. Hernandez-Nieto Pethema Spanish Cooperative Group for Hematological Malignancies Treatment, Spanish Society of Hematology, Spain
  • A. Domingo Pethema Spanish Cooperative Group for Hematological Malignancies Treatment, Spanish Society of Hematology, Spain
  • J. Marin Pethema Spanish Cooperative Group for Hematological Malignancies Treatment, Spanish Society of Hematology, Spain
  • M. C. Guzman Pethema Spanish Cooperative Group for Hematological Malignancies Treatment, Spanish Society of Hematology, Spain
  • J. Estape Pethema Spanish Cooperative Group for Hematological Malignancies Treatment, Spanish Society of Hematology, Spain

DOI:

https://doi.org/10.3109/02841868909111251

Keywords:

Acute myeloblastic leukemia, post-remission therapy, early consolidation, maintenance, randomized trial

Abstract

During a 5-year period 203 previously untreated patients with acute myeloblasts leukemia entered an intensive induction chemotherapy regimen with daunorubicin, cytosine arabinoside, 6-thioguanine, vincristine and prednisone (DATOP). The complete remission rate was 64%. Patients in complete remission were randomly assigned to 3 courses of early consolidation with DATOP at lower dosage followed by maintenance chemotherapy, or to the same maintenance regimen in the absence of any consolidation courses. No significant differences were found between these options concerning disease-free survival (median 7.0 vs. 9.8 months; p>0.10) or survival (median 15.8 vs. 19.4 months; p>0.10). This study, in addition to the few previously reported randomized trials, suggests that early low-dose consolidation adds no benefit to maintenance chemotherapy in acute myeloblasts leukemia once complete remission has been achieved.

Downloads

Download data is not yet available.

Downloads

Published

1989-01-01

How to Cite

Maldonado, J., Gardella, S., Rodriguez Fernandez, J. M., Parody, R., Muncunill, J., Vivancos, P., … Estape, J. (1989). Post-Remission Therapy in Acute Myeloblastic Leukemia a randomized trial comparing early consolidation plus maintenance versus maintenance therapy alone. Acta Oncologica, 28(2), 223–226. https://doi.org/10.3109/02841868909111251

Issue

Vol. 28 No. 2 (1989): Acta Oncologica

Section

Articles